Search

Heart palpitations are the sensations or feelings that accompany an excessively rapid, skip-beat, or fluttering heartbeat. Heart palpitations can be brought on by a variety of factors, such as anxiety, tension, fear, caffeine, nicotine, some medications, dietpills, physical activity, and fever. Herbal remedies have long been utilized widely in the therapeutic management of palpitations because available synthetic medications have substantial negative effects. The purpose of this study is to assess the safety and effectiveness of the Unani medication Jawarish-e-Shahi in patients experiencing palpitations. The information provided here is an open-level, multicentric clinical study that was carried out at the "Regional Research Institute of Unani Medicine in Aligarh", Uttar Pradesh, from 2016 to 2019 on 74 cases of palpitation streated with Jawarish-e-Shahi. A p-value of<0.05 was proved to be significant in the statistical analysis of the presented data, which was conducted using one-way analysis of variance (ANOVA) and Dunnett's test. The study's findings, which were compared to baseline data from various follow-ups of palpitation cases treated with Jawarish-e-Shahi, demonstrated a notable improvement in a number of palpitation symptoms, including anxiety, perspiration, nausea, vomiting, and chest heaviness. A significant decline in diastolic pressure and pulse rate had also been observed. Reduction in number of pallor (pale appearance of patients) in baseline, 1st follow-up and post-treatment had been noted. Based on the investigation, the Unani medicine is safe and non-toxic. More research on a large size of population with palpitations is suggested for further study. [ABSTRACT FROM AUTHOR]

Present study evaluated the therapeutic efficacy and safety of two Unani compound drugs namely Majun-e-Suranjan and Habb-e-Azraqi in cases of gout on modern scientific parameters viz., clinical, biochemical and haematological. This work was conducted at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2014-2019. 71 people were chosen from the pool of patients visiting the outpatient department (OPD). Patients received the Unani medicines Majun-e-Suranjan in a dose of 5.0 g and Habb-e-Azraqi in a dose of 1 pill (250 mg) twice daily after meals for a period of 56-days. One-way analysis of variance (ANOVA) was used for the analysis of data, and the statistical significance of the findings was determined by Dennett's test. The study reveals that the two Unani medicines are safe, non-toxic, and significantly relieve the symptoms of gouty arthritis. It is suggested to conduct more research among a large population. [ABSTRACT FROM AUTHOR]

Liver plays a major role in metabolism and excretion of xenobiotics. Liver dysfunction is a major health problem that challenges health care professionals, pharmaceutical industry and drug regulatory agencies. The most common symptoms are fatigue and discomfort in abdomen while in patients who are obese with BMI > 25, about one third have metabolic syndromes. The present clinical research was conducted in Regional Research Institute of Unani Medicine, Aligarh. The patients under trial were selected from GOPD of institute for obesity and it was observed that out of total registered patients' approx 28% have elevated liver enzymes from its normal range without any sign and symptom of hepatitis etc. Total 23 patients were selected from the study whose liver enzymes (SGOT, SGPT and ALP) were high at the baseline. Unani pharmacopoeial drug Jawārish bisbāsā 7 g daily was prescribed with lukewarm water in the morning and evening empty stomach for 8 weeks. At the end of study the result were compared with base line. It was observed that Jawārish bisbāsā significantly reduced the liver enzymes, e.g. SGOT, SGPT, Alkaline Phosphatase in comparison to baseline values. It may be concluded that Jawārish bisbāsā showed hepatoprotective effect in this clinical study. [ABSTRACT FROM AUTHOR]

Background: Regardless of amazing advancements in contemporary science & technology, it is not possible to provide everyone access to high-quality healthcare. Traditional medicine, in particular Ayurveda and Unani medicine, is regarded as a major global provider of healthcare. This manuscript is aimed to provide the promulgation of Unani Medicine in contemporary healthcare system. Methods: A in-depth literature analysis was successfully carried out from year 2006 to 2021 to collate the information on the advancement, growth and development of the Unani System of Medicine (USM). The search strategy was performed with recent surveys, articles and the numerous initiatives undertaken by the Ministry of AYUSH, Centre council in research in unani medicine (CCRUM) & other institutions on Unani education and research. Additionally, the updated market analysis (2020-2022) comprises import, export and trade data on Unani medicines is also described. From what we know, this review is the first of a kind to describe the domestic and global perspective of Unani medicine with and its global development. Results: The multi-disciplinary, multi-centric research initiatives of the Ministry of AYUSH have resulted in an increase in medical facilities and education in the Unani System of Medicine. With 1748 Unani dispensaries and 3947 beds in Unani hospitals, the number of these facilities has grown at a 2.4% annual pace between 2011 and 2021. Conclusion: There is tremendous growth in Unani as well as in herbal industry. Unani Medicines have shown their potential and need for better drugs and remedies against various diseases. The knowledge on import and export and the information on research and education enable to work more in this domain. These initiatives favour the World Health Organisation advocating Unani medicine as a better alternative system against various diseases. [ABSTRACT FROM AUTHOR]

Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative. Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management. Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14. This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003). Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group. [ABSTRACT FROM AUTHOR]

Arthritis is described in Unani system of Medicine under a broad term Waja'al-Mafāsil which covers entire joint disorders like inflammatory, non-inflammatory, infectious, metabolic and other musculoskeletal disorders. According to Unani concept, the pathological changes in the joints are caused mainly by derangement of humoural (Akhlat) temperament and accumulation of Fasid madda (Morbid material) in the joint spaces. The main principles of treatment in Unani system of Medicine include Ilaj bi'l Ghidha (Dieto-therapy), Ilaj bi'l Tadbir (Regimenal therapy) and Ilaj bi'l Dawa (Pharmacotherapy). All the said principles are recommended for the treatment of Waja'al-Mafāsil. The aim of treatment for patient with Waja'al-Mafāsil is to reduce morbidity and disability. In India it affects 15% (180 million) people. Ancient Unani scholars have elaborately described Waja'al-Mafāsil and managed with multidimensional approach, whereas with the present day management of disease mainly with non-steroidal anti-inflammatory drugs (NSAIDs) which have large number of adverse effects. This review article highlight the salient features describing arthritis with reference to Waja'al-Mafāsil for empathizing disease condition as enunciated by Unani scholars to provide a better alternative in terms of cost effective managements and side effects. [ABSTRACT FROM AUTHOR]

Today the world is witnessing a rise in incidence of diseases and the demand for affordable health care has increased manifold. An effective and robust public health system is the need of the hour to improve the health and wellbeing of people across the globe. Unani Medicine is a holistic system of medicine, which offers indigenous and effective therapies, which are already helping millions of people across the globe in living a healthy life. Unani medicine gained momentum as an effective alternative to conventional medicine due to its systematic approach towards diagnosis and treatment of diseases, effective management of lifestyle disorders and primary focus on prevention of ailments. This system of medicine, which has its origin from Greece, today has a presence in many parts of the globe. Besides India, it is practiced in several countries like Bangladesh, South Africa, Pakistan, Iran, United Arab Emirates and Sri Lanka etc. The Government of India facilitated the growth and development of Unani medicine by recognizing its utility and scope and integrated it into healthcare delivery system. With its wide network of quality educational institutions, comprehensive healthcare facilities, state of the art research institutions and quality drug manufacturing industries and on account of its utilization by a large number of people for their healthcare needs, India has emerged as the global leader in Unani medicine. Concerted efforts are being made to carry out high quality, evidence based research and to make the system more accessible and affordable. Unani medicine can contribute a wealth of knowledge and experience for the benefit of human kind and has the potential to be one of the major contributors in health care delivery in other parts of the globe. [ABSTRACT FROM AUTHOR]

Aim of the Study: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. Materials and Methods: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group 'A' thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group 'B' thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group 'C' 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. Results: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well. [ABSTRACT FROM AUTHOR]

The study aimed to evaluate the effect of cupping therapy at a clinical setting for knee osteoarthritis. A randomized, controlled clinical trial was conducted. Cupping was performed on 0-6th day; 9-11th day and 14th day, i.e., 11 sittings follow-up to determine longer term carryover of treatment effects utilizing both objective and subjective assessment. The assessment was performed before and after treatment spreading over a period of 15 days. The results of this study shows significant and better results in the overall management of knee osteoarthritis, particularly in relieving pain, edema, stiffness and disability. The efficacy of treatment with cupping therapy in relieving signs and symptoms of knee osteoarthritis is comparable to that of acetaminophen 650 mg thrice a day orally, in terms of analgesia, anti-inflammatory and resolution of edema with minimal and temporary side-effects like echymosis and blister formation while as control drug has greater side-effects particularly on upper gastrointestinal tract. It is recommended that further studies are conducted with a larger study samples and of longer duration. [ABSTRACT FROM AUTHOR]

The aim of this study is to evaluate the efficacy of a Unani formulation in hypertension. A total of 90 patients with total cholesterol level of more than 220 mg/dl with associated conditions were included in this study. A total of 30 patients having a mean systolic blood pressure (BP) of 133.86 mmHg comprising Group A received Unani formulation Safoof-e-Muhazzil (SM) in its classical powder form in the dose of 5 g twice a day orally. Group B comprising of 30 patients with a mean systolic BP of 133.13 mmHg received same drug, but in compressed tablet form in the same dosage, whereas, 30 patients comprising Group C with a mean systolic BP of 129.45 mmHg, received Atorvastatin 10 mg as a standard control. Patients were evaluated on each follow-up at 2nd, 4th and 6th week. The mean systolic BP in Group A and B before treatment was 133.86 ± 3.028 mmHg and 133.13 ± 2.852 mmHg, which significantly decreased to 119.33 ± 1.922 mmHg (P < 0.001) and 119 ± 1.760 mmHg (P < 0.001) respectively. In the control Group C before treatment BP was 129.45 ± 2.499 mmHg and after treatment it significantly decreased to 124.34 ± 1.794 mmHg (P < 0.01). The percentage change after treatment was 10.85%, 10.61% and 3.94% respectively in each group. Mean diastolic BP in Group A and B before treatment was 85.06 ± 2.11 mmHg and 84.56 ± 1.5 mmHg, which significantly decreased to 79.06 ± 1.56 mmHg (P < 0.001) and 79.96 ± 1.15 mmHg (P < 0.001) respectively, BP before treatment in Group C was 83.23 ± 1.588 mmHg, which was decreased to 124.34 ± 1.794 mmHg (P < 0.01). The study results indicate that the test drug was quite effective in reducing both systolic as well as diastolic BP. [ABSTRACT FROM AUTHOR]

Objectives: To assess the awareness, practice, and utilization pattern of Unani medicine among the general population of Trilokpuri, East Delhi., Materials and Methods: A cross-sectional, observational descriptive survey was conducted in New Delhi using pretested, predesigned, and structured questionnaire to assess the awareness and utilization pattern of Unani medicine on a sample size of 100 subjects., Result: Out of 100 subjects, 60% were males and 40% were females with mean age 38.96 ± 9.12 years, ranged between 18 and 65 years. The awareness about Unani medicine was found in 67% of adopted population, while 57% population among them preferred Unani system of medicine as a mode of treatment. Unani is preferred because of minimal side effects associated as reported by 47% users. On the other hand, among nonuser ( n = 29), 48% population do not prefer Unani medicine because of its slow action. Very few (2.6%) users adopted Unani medicine exclusively, while most of them preferred Unani as an adjuvant with allopathic. Unani medicine is preferred mainly for the management of musculoskeletal disorders (35%), followed by GIT disorders (19%) and their related disorders., Conclusion: The awareness level regarding Unani medicine is good rather utilization of is relatively lower as compared to modern system of medicine. There is a need and scope for promotion of health education as well as improvement in the people's attitude towards Unani system of medicine., Competing Interests: There are no conflicts of interest., (Copyright: © 2022 Journal of Pharmacy and Bioallied Sciences.)